French Survey Examines Medical Cannabis And Parkinson’s Disease
A team of researchers affiliated with various academic and health institutions in France recently examined results from a survey that asked French patients diagnosed with Parkinson’s disease (PD) about their medical cannabis use and how it impacts their quality of life. The analysis results were published in the journal Parkinson’s Disease.
“In the context of suboptimal symptom management, or due to the appeal of more natural treatments, PD patients may seek alternative approaches to care, including consuming cannabis-based products. In line with findings from subsequent reviews, Urbi et al.’s 2021 meta-analysis concluded that in terms of cannabis use in PD patients, “a potential benefit was identified with respect to alleviation of PD–related tremor, anxiety, pain, improvement of sleep quality, and quality of life”.” the researchers wrote.
“Regression analyses helped identify factors associated with current cannabis and CBD use (regardless of their form). Patterns of use and self-reported effects were also documented.” the researchers stated about their methodology.
“The study sample comprised 1136 participants, with a median age of 68 years. Six percent (5.9%) and 17.9% reported using cannabis and CBD, respectively. Both substances were associated with better knowledge of cannabinoids and a poor self-perceived household economic situation. The most common routes of cannabis administration were oral ingestion (44.8%) and smoking (41.4%); for CBD, they were oral ingestion (82.8%) and smoking (6.4%). Users reported that cannabis and CBD were very effective for sleep disorders, pain, and rigidity/cramps. The satisfaction level for both substances was also high.” the researchers stated about their findings.
“Cannabis and CBD use among people with PD was associated with better knowledge about cannabinoids and a poor self-perceived household economic situation. Furthermore, users reported high levels of satisfaction for both substances. An enhanced communication with healthcare providers and facilitated access to safe cannabis/CBD products are needed in France to enable people with PD to maximize the benefits of cannabinoids when clinically appropriate.” the researchers concluded.
According to international researchers, the prevalence of Parkinson’s disease has doubled in the past 25 years, with an estimated 8.5 million individuals living with the serious health condition.
“Parkinson’s disease resulted in 5.8 million disability-adjusted life years, an increase of 81% since 2000, and caused 329,000 deaths, an increase of over 100% since 2000.” states the World Health Organization.
